# Agenus Inc: overview AGEN · Nasdaq · CIK 1098972 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/agen.md) · [Financials](/companies/agen/financials.md) · [Filings](/companies/agen/filings.md) · [Insiders](/companies/agen/insiders.md) Latest reported revenue: [$34.5m](/filings/0001193125-26-340363.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-340363). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [25.1](/filings/0001193125-25-274554.md) | [26.8 d](/filings/0001193125-26-108632.md) | [24.1](/filings/0001193125-26-217082.md) | [25.7](/filings/0001193125-26-340363.md) | [30.2](/filings/0001193125-25-274554.md) | [34.2 d](/filings/0001193125-26-108632.md) | [33.7](/filings/0001193125-26-217082.md) | [34.5](/filings/0001193125-26-340363.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(125.5%)](/filings/0001193125-25-274554.md) | [(96.5%) d](/filings/0001193125-26-108632.md) | [(55.3%)](/filings/0001193125-26-217082.md) | [(65.0%)](/filings/0001193125-26-340363.md) | [(15.0%)](/filings/0001193125-25-274554.md) | [42.1% d](/filings/0001193125-26-108632.md) | [44.6%](/filings/0001193125-26-217082.md) | [32.7%](/filings/0001193125-26-340363.md) | | Net margin | % | [(267.7%)](/filings/0001193125-25-274554.md) | [(174.4%) d](/filings/0001193125-26-108632.md) | [(109.6%)](/filings/0001193125-26-340363.md) | [(116.8%)](/filings/0001193125-26-340363.md) | [211.4%](/filings/0001193125-25-274554.md) | [(31.0%) d](/filings/0001193125-26-108632.md) | [116.2%](/filings/0001193125-26-340363.md) | [(1.6%)](/filings/0001193125-26-340363.md) | | Diluted EPS | $ per share | [(3.08)](/filings/0001193125-25-274554.md) | not reported | [(1.03)](/filings/0001193125-26-217082.md) | [(1.00)](/filings/0001193125-26-340363.md) | [1.94](/filings/0001193125-25-274554.md) | not reported | [1.02](/filings/0001193125-26-217082.md) | [(0.01)](/filings/0001193125-26-340363.md) | | Free cash flow | $m | [(53.3) d](/filings/0001193125-25-274554.md) | [(28.7) d](/filings/0001193125-26-108632.md) | [(25.6)](/filings/0001193125-26-217082.md) | [(20.2) d](/filings/0001193125-26-340363.md) | [(14.7) d](/filings/0001193125-25-274554.md) | [(16.6) d](/filings/0001193125-26-108632.md) | [(36.0)](/filings/0001193125-26-217082.md) | [(31.2) d](/filings/0001193125-26-340363.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [296](/filings/0000950170-24-031620.md) | [98.0](/filings/0000950170-25-040289.md) | [156](/filings/0001193125-26-108632.md) | [103](/filings/0001193125-26-108632.md) | [114](/filings/0001193125-26-108632.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [8.7%](/filings/0000950170-24-031620.md) | [(183.0%)](/filings/0000950170-25-040289.md) | [(102.1%)](/filings/0001193125-26-108632.md) | [(116.4%)](/filings/0001193125-26-108632.md) | [(17.7%)](/filings/0001193125-26-108632.md) | | Net margin | % | [(9.7%)](/filings/0000950170-24-031620.md) | [(235.3%)](/filings/0000950170-25-040289.md) | [(164.7%)](/filings/0001193125-26-108632.md) | [(224.5%)](/filings/0001193125-26-108632.md) | [(2.7%)](/filings/0001193125-26-108632.md) | | Diluted EPS | $ per share | [(0.11)](/filings/0000950170-24-031620.md) | [(15.64)](/filings/0000950170-25-040289.md) | [(13.75)](/filings/0001193125-26-108632.md) | [(10.59)](/filings/0001193125-26-108632.md) | [0.00](/filings/0001193125-26-108632.md) | | Free cash flow | $m | [(23.7)](/filings/0000950170-24-031620.md) | [(228)](/filings/0000950170-25-040289.md) | [(234)](/filings/0001193125-26-108632.md) | [(159)](/filings/0001193125-26-108632.md) | [(77.2)](/filings/0001193125-26-108632.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/agen/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $7.8m | 2,564,884 | | Added +2,019,222 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.1m | 1,676,096 | | Added +235,864 | | [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $4.4m | 1,427,587 | | Added +232,478 | | [Siren, L.L.C.](/funds/2005245.md) | 2026-06-30 | $3.3m | 1,064,250 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.2m | 1,035,040 | | Added +686,645 | | [MACKENZIE FINANCIAL CORP](/funds/919859.md) | 2026-06-30 | $2.2m | 714,175 | | New +714,175 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $1.4m | 448,383 | | Added +416,929 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $1.3m | 439,621 | | Reduced −248,582 | | [RAYMOND JAMES FINANCIAL INC](/funds/720005.md) | 2026-06-30 | $1.3m | 430,078 | | Added +190,524 | | [GLOBEFLEX CAPITAL L P](/funds/921531.md) | 2026-06-30 | $1.3m | 418,581 | | New +418,581 | ## Recent filings [All 1,860 filings](/companies/agen/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-18 | 20:30 ET | [8-K](/filings/0001193125-26-355559.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity | 0001193125-26-355559 | | 2026-08-13 | 01:30 ET | [8-K](/filings/0001193125-26-347518.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-347518 | | 2026-08-11 | 20:30 ET | [8-K](/filings/0001193125-26-344783.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-344783 | | 2026-08-07 | 20:30 ET | [10-Q](/filings/0001193125-26-340363.md) | Quarterly report, period 2026-06-30 | 0001193125-26-340363 | | 2026-08-06 | 11:52 ET | [8-K](/filings/0001193125-26-336780.md) | 2.02 Results of operations | 0001193125-26-336780 | | 2026-07-13 | 10:30 ET | [8-K](/filings/0001193125-26-301414.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-301414 | | 2026-07-06 | 20:10 ET | [8-K](/filings/0001193125-26-296186.md) | 1.01 Entry into a material agreement | 0001193125-26-296186 | | 2026-06-23 | 14:14 ET | [8-K](/filings/0001193125-26-278647.md) | 5.07 Shareholder vote results | 0001193125-26-278647 | | 2026-05-15 | 20:08 ET | [8-K](/filings/0001193125-26-226693.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-226693 | | 2026-05-11 | 21:04 ET | [10-Q](/filings/0001193125-26-217082.md) | Quarterly report, period 2026-03-31 | 0001193125-26-217082 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-108632.md), filed Mar 16, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/dc947bea-826b-47e9-a893-8c0abdd76783) ## About the filer - CIK: 1098972 - Tickers: AGEN - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.